INNOVATION
With continuous innovation as a key driver for our sustainable growth, our R&D teams work relentlessly to help ensure we meet individual consumer and patient needs with superior outcomes.
Currently, two of our highest priorities are to complete the clinical development of nemolizumab, an investigational therapy for patients with atopic dermatitis and prurigo nodularis as well as QM-1114, a novel, ready-to-use, liquid formulation of botulinum toxin for the treatment of glabellar lines and lateral canthal lines.
We partner with companies and institutions around the world to bring together complementary strengths and find innovative ways to improve our consumers’ and patients’ quality of life.
OUR POLICY ON EXPANDED ACCESS PROGRAM
Galderma believes clinical trials are the most appropriate way for patients to access investigational medicines developed by Galderma. In these trials, the safety and efficacy of investigational medicines are rigorously assessed by Galderma and the relevant regulatory agencies in order to understand the medicine’s benefits, risks, and appropriate use, including whether or not it should be approved as a therapy for its intended use. Obtaining regulatory approval is the best way to bring safe and effective medicines to the greatest number of patients who may benefit from treatment.
At this time, Galderma does not have an expanded access program that allows patients to have access to the company’s investigational therapies outside of clinical trials or prior to FDA approval. Galderma may update this policy as drug development programs are progressing and reassess the approach to expanded access programs. Should patients, families, or physicians have any questions, please contact our Medical Information department by email at Medicalinfo-trials@galderma.com
